BiotechTube
Home/Pipeline/Multiple Programs

Multiple Programs

Undisclosed solid tumors

DiscoveryActive

Key Facts

Indication
Undisclosed solid tumors
Phase
Discovery
Status
Active
Company
Aktis Oncology

About Aktis Oncology

Aktis Oncology's mission is to transform cancer care by developing next-generation targeted alpha radiopharmaceuticals for solid tumors historically beyond the reach of this modality. The company's core innovation is a proprietary miniprotein radioconjugate platform engineered for deep tumor penetration, rapid systemic clearance, and high tumor residence time. Since its 2019 founding, Aktis has advanced a pipeline led by AKY-1189 (Nectin-4) into Phase 1b and AKY-2519 (B7-H3) into IND-enabling studies, culminating in a successful public listing in 2024. Its strategy is to leverage its platform to build a broad pipeline addressing large-market epithelial cancers.

View full company profile

Therapeutic Areas

OncologySolid Tumors

Other Undisclosed solid tumors Drugs

DrugCompanyPhase
Macrophage-Targeting Agonist AntibodyBolt BiotherapeuticsPhase 1
IMA204Immatics BiotechnologiesPhase 1
TAR002TargImmune TherapeuticsPre-clinical
TAR003TargImmune TherapeuticsPre-clinical
Proprietary TCR-NK PlatformZelluna ImmunotherapyPreclinical
ERAS-113ErascaDiscovery
BAT5506CompugenPreclinical
Precision DACsPrelude TherapeuticsDiscovery
V2ACT ImmunotherapyGeneluxPhase 1
ATOR-4066alligator-bioscience-abDiscovery/Preclinical
ACR-6840Acrivon TherapeuticsPreclinical
ADC ProgramLantern PharmaDiscovery/Preclinical